3 Semaglutide (Wegovy) Efficacy: In the STEP 1 trial involving adults with overweight or obesity without diabetes, those taking Wegovy 2.4 mg once weekly for 68 weeks achieved an average weight loss of approximately 14.9%, compared to 2.4% in the placebo group
Key Takeaways of the Global Tirzepatide Market Type 2 diabetes holds the largest market share by indication, accounting for an expected in 2026, due to the growing global prevalence of type 2 diabetes
The mean changes from baseline to week 26 were -1.4 kg, -2.3 kg and -3.7 kg in the placebo, semaglutide tablets7 mg and semaglutide tablets 14 mg arms, respectively
The decision depends on your overall health, other medications, and the risk-benefit balance
[11] In practice, sermorelin is almost never used during pregnancy, since treating chronic growth hormone deficiency can typically be deferred and other therapies (if needed) would be chosen if GH support was truly required